Remove Clinic Remove Diagnostic Remove Pharmaceutical
article thumbnail

RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

Imaging Technology

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

article thumbnail

Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer

Imaging Technology

Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Board of Directors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

Imaging Technology

Currently, when treating metastatic breast cancer patients, oncologists base clinical decisions on diagnostic tools including biopsy results which only represent the sampled area of the tumor. In the U.S., FES PET, like FDG PET, is now included in the NCCN Guidelines. The NCCN is a not-for-profit alliance of 33 leading U.S.

Clinic 94
article thumbnail

GE HealthCare and MediView Announce the World's First Installation and Clinical Use of Augmented Reality Interventional Suite that Aims to Transform the Practice of Interventional Radiology

Imaging Technology

milla1cf Fri, 06/21/2024 - 20:24 June 21, 2024 — GE HealthCare , a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MediView XR Inc., Proceduralists must refer to standard of care imaging and prioritize clinical experience and/or judgment when using the OmnifyXR system.

article thumbnail

SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

Imaging Technology

-based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). SOFIE will continue its clinical development and commercialization program with [18F]FAPI-74 in the U.S. Financial terms were not disclosed. Sherly Mosessian , Ph.D,

article thumbnail

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Imaging Technology

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

article thumbnail

NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production

Imaging Technology

Medical isotopes are essential for a wide range of diagnostic and therapeutic procedures, including cancer treatments and advanced imaging techniques. An active DMF enables clinical investigators or pharmaceutical companies to reference the filing in their regulatory submissions. a subsidiary of BWX Technologies, Inc.

Medical 105